PCP
AXSM icon

Perbak Capital Partners’s Axsome Therapeutics AXSM Stock Holding History

Perbak Capital Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,058
Closed -$517K – 30
2026
Q1 		$517K Buy
3,058
+1,856
+154% +$321K 0.13% 185
2025
Q4 		$220K Sell
1,202
-5,111
-81% -$714K 0.07% 205
2025
Q3 		$767K Buy
6,313
+1,585
+34% +$179K 0.14% 170
2025
Q2 		$494K Buy
+4,728
New +$501K 0.11% 186

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Perbak Capital Partners's AXSM Position: Q2 2026 in Review

Perbak Capital Partners sold out of Axsome Therapeutics (AXSM) in Q2 2026, closing a stake of 3,058 shares — an estimated $517K sold.

Perbak Capital Partners first reported a position in AXSM in Q2 2025 and held it in 4 quarters. The position peaked at $767K in Q3 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Perbak Capital Partners reported no remaining Axsome Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Perbak Capital Partners sold 3,058 Axsome Therapeutics shares in Q2 2026, an estimated $517K.
  • Perbak Capital Partners first reported a position in Axsome Therapeutics in Q2 2025 and held it in 4 quarters.
  • Perbak Capital Partners's Axsome Therapeutics position peaked at $767K in Q3 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Perbak Capital Partners's 13F filing for Q2 2026.